FDA Tightens Restrictions for Transmucosal Fentanyl Products

New changes to REMS safety programs will require stronger treatment documentation and oversight.

Patient Engagement is Personal: How to Help Injured Workers Help Themselves

Patient engagement can lead to better health outcomes, but not all engagement strategies are equally effective.

The Impact of the Changing Workforce

The workforce is aging, getting younger, and gaining more women, all at once. What does that mean for claims management?

Marijuana Continues to Take Major Steps Forward

Congress may soon clear federal restrictions to processing marijuana transactions, while the FDA asks for feedback on handling marijuana products.

Oklahoma Reaches $270 Million Settlement with Opioid Manufacturer

Various state and local governments have sued drug developers for the harms of the opioid epidemic, and this could be the first of many settlements.

Tanezumab Trials Yield Positive Results for Pain Management

Phase 3 clinical trials for this non-opioid drug demonstrate significant reductions in pain for osteoarthritis and chronic low-back pain.

Opioid Imbalance: Risk Disparities Among Diverse Patient Populations

Demographic factors such as gender, ethnicity, socioeconomic status, age, and location can impact opioid risks.

Tackling Topicals: Clinicians Takes Notice

Despite having little clinical impact, topical creams continue to be utilized widely in workers’ comp.

The Drug Price Debate

Federal lawmakers and administrative agencies continue to investigate how to best lower ever-increasing drug prices.

FDA Establishes Guidance for Brain-Computer Interface Technologies

Can special implants in the brain override paralysis? The FDA believes one day they could.

FDA Nudges Developers to Create Over-the-Counter Naloxone

The FDA created special drug labels to clear a development hurdle and encourage manufacturers.

Marijuana – What to Expect in 2019 and Beyond

Dr. Robert Goldberg and Sandy Shtab talk with Risk & Insurance about changing attitudes and policies around medical marijuana, its potential role in reducing reliance on opioids, and what this can mean for payers, employers, patients and PBMs.

Troubling Trends for Benzodiazepines

Prescribing has doubled since 2003, overdose deaths quadrupled since 1996, and misuse accounts for 20% of benzodiazepine use.

PTSD Coverage: More States Draft Legislation

Kentucky, Connecticut, Idaho, and West Virginia proposed bills to make PTSD compensable for first responders.

Opioid Marketing Tied to Higher Prescribing and Overdose

A new JAMA study finds that increased county-level opioid marketing was tied to elevated overdose mortality.

FDA Approves Two New Strengths of Apadaz

The opioid prodrug for acute pain will soon be available in both a stronger and weaker dose.

What’s Ahead for 2019 Workers’ Comp Regulations

As 2018’s legislative trends continue to spill into 2019, what big initiatives might impact workers’ comp this year?

JAMA Examines Association of Early Physical Therapy with Long-Term Opioid Use

An analysis of 90,000 private claims explores the relationship between early PT and reduced long-term opioid use in musculoskeletal pain.

The Legality of Self-Referrals

Can doctors in certain states refer patients to pharmacies which they partially own?

The Buzz Behind Digital Therapeutics

Will doctors one day prescribe apps meant to drive behavior changes instead of drugs?

FDA Approves First Prescription App for Opioid Use Disorder

The reSET-O app uses cognitive behavioral therapy techniques to assist patients engaged in medication-assisted therapy for opioid dependence.

Hero’s Welcome: Growing PTSD Coverage for First Responders

Formulary and claims management considerations for populations at risk for “mental-only” cases of PTSD.

New Guidelines for Opioid-Induced Constipation

The American Gastroenterological Association released guidance on properly prescribing medications for OIC.

Marijuana Use Rising Among Older Populations

Marijuana use among adults aged 50-64 tripled from 2002-2014.

In Case You Missed It: 5 Takeaways on Value-Based Models in Work Comp

Dr. Silvia Sacalis of Healthesystems teamed up with Dr. Adam Seidner of The Hartford for a session at NWCDC – here are 5 key takeaways.

FDA Approves New Opioid, Dsuvia

Five-to-ten times stronger than fentanyl, this drug is not for consumer use, and many claim it could worsen the opioid crisis.

The Opioid Crisis: Our Defining Moment

Healthesystems’ clinical leaders comment on the collective responsibility of healthcare entities, providers, and legislators to increase efforts that will help stem opioid overprescribing, misuse and overdose.

Midterm Marijuana Updates

More states allow for the legalization of recreational and medical marijuana, while others consider insurance reimbursement.

JAMA Examines Persistent Opioid Use in Workers’ Comp Patients

A study of 9,596 claimants who filled an opioid prescription found that 30% were still taking opioids 90 days later.

Healthesystems at NWCDC 2018

Join our VP of Clinical Services on December 6th in Las Vegas for a presentation on value-based care in workers’ comp.

DEA Reschedules Epidiolex

The marijuana-derived seizure drug now sits at schedule V, facing far fewer prescribing and dispensing restrictions.

Dr. Silvia Sacalis Discusses Medication Red Flags with Risk & Insurance

Healthesystems’ VP of Clinical Services offers insight into prescriptions in workers’ comp claims that should raise concerns.

New Jersey Bill Pushes for Medical Marijuana Reimbursement

Assembly No. 4505 may solidify precedence recently made by a judge from the Division of Workers’ Compensation.

National Safety Council Issues Report on Workplace Fatigue

Common risk factors can increase worker fatigue, leading to more frequent workplace injuries and a loss of productivity.

Federal Opioid Reform Bill Signed into Law

With an enormous range of initiatives to prevent and treat opioid use disorder, the bill has officially been signed by the President.

FDA Approves New Dosage for Opioid Dependence Therapy

Cassipa (buprenorphine and naloxone) sublingual film delivers a new dosage for the treatment of opioid dependence.

Dr. Silvia Sacalis Discusses Polypharmacy with WC Magazine

Healthesystems’ VP of Clinical Services explains how too many drugs in a claim can cause health concerns, and what can be done to prevent them.

FDA Reassesses Opioid Policies

The FDA is working to create new opioid prescribing practices and guidelines, while also shifting drug development priorities for pain medications.

CWCI Releases Polypharmacy Report

According to 2016-2017 data, over 20% of polypharmacy claims are over 10 years old, with more than 50% of them for patients aged 50 and older.

Massachusetts Study Links Occupation to Opioid Overdose Deaths

On average, construction workers are six times more likely to die from an opioid overdose death, more than any other occupation.

Dr. Robert Goldberg Comments on DEA Opioid Manufacturing Quotas

Healthesystems’ Chief Medical Officer spoke with WorkCompCentral regarding DEA plans to reduce opioid manufacturing.

FDA Accepts New Drug Application for Opioid NKTR-181

NKTR-181 is supposed to offer a lower frequency of opioid side effects. But are more opioids really the solution we need to the opioid crisis?

Sandy Shtab Discusses the Need to Modernize Regulation with WorkCompWire

Healthesystems’ AVP of Advocacy & Compliance explains how regulation has been unable to keep pace with healthcare innovation & technology.

PTSD Legislation Continues to Grow

More states cover PTSD without physical injuries for first responders, and 24 states allow PTSD patients to use medical marijuana.

New Developments in Migraine Medications

A new wave of drugs that suppress CGRP proteins to reduce migraines could be on the horizon.

FDA Proposes New Clinical Endpoints for Development of Opioid-Use Disorder Drugs

Drugs to treat opioid dependence could be approved under new clinical endpoints other than reducing opioid use.

Healthe Clinical Leaders in the News

Our Chief Medical Officer and VP of Clinical Services comment on matters such as the use of anticonvulsants to treat pain and opioid prescriptions for inpatients.

New Opioid in Development May Offer Reduced Risk Profile

Phase 2/3 clinical trial results for Korsuva demonstrate pain relief with fewer side effects.

Mark of the Millennial: Managed Care for a New Generation

Millennials are more diverse and more open to alternative therapies, medical marijuana, healthcare technology, and dialogue surrounding psychosocial concerns.

Support for Marijuana Continues to Grow Across the Nation

A flurry of recent developments continues to bring the medical marijuana debate front and center, including further legalization, a Senate bill, a drug approval, and more.

JAMA Study Questions the Effectiveness of Negative Pressure Wound Therapy

In a randomized clinical trial of 460 patients, researchers found the treatment to have similar impact on self-rated disability as standard wound dressing.

Healthesystems at WCIEC Orlando 2018

Visit Healthesystems in booth #914 to see how we explore the conference’s “Cosmic” theme, and for a chance to win a $250 gift card.

Drug Approvals Impacting Workers’ Comp

The FDA recently approved drugs to treat opioid dependence, migraines, and rheumatoid arthritis.

The Burden of Opioid-Related Mortality in the United States

Among many findings, JAMA reports that 20% of deaths among those aged 25-34 were opioid-related.

More States Pass Opioid Prescription Limits

Within the last month, laws have passed in Tennessee, Colorado, South Carolina, Oklahoma, and Hawaii.

IQVIA Reports on Global Oncology Trends

Global spending on cancer therapies now exceeds $133 billion.

Healthe Leaders Comment on Clinical Use of Marijuana & MDMA

Our Chief Medical Officer and VP of Clinical Services comment on the clinical use of ecstasy and marijuana.

FDA Encourages Drug Developers to Focus on Buprenorphine Depot Products

A newly released draft guidance encourages the development of more sustained-release buprenorphine products.

WCRI Releases CompScope Benchmarks

In-depth reports for 16 different states examine medical payments, costs, duration of disability, and more.

Illinois Bill May Allow Patients to Trade Opioids for Marijuana

Senate Bill 336 passed with a 44-6 vote and is now headed to the House.

The Craze Over Kratom

Kratom continues to grow in popularity as a drug for pain and opioid withdrawal, despite concerns from the FDA, CDC and DEA.

Four Current and Near-Future Drug Trends Impacting Rx Management

In a special partner post with WorkCompWire, Healthesystems discusses developments in pain management, specialty drugs, and more.

Opioid Withdrawal Drug Closer to Approval

If approved, Lucemyra (lofexidine) would be the first non-opioid drug approved to treat the symptoms of opioid withdrawal.

Dr. Silvia Sacalis Discusses Value-Based Care with WorkCompWire

Healthesystems’ VP of Clinical Services discusses how workers’ comp is embracing a value-driven approach.

WCIRB Reports on Chronic Opioid Use and Weaning

A new study analyzes the characteristics of chronic opioid use claims, while also examining opioid weaning data.

PTSD Bills Gain Momentum in Workers’ Comp

A Florida bill was recently signed into law, and states such as Arizona, Utah, Connecticut, and Oregon may follow suit.

More States Embrace Closed Drug Formularies

Indiana and Kentucky signed off on formulary bills, while other states continue to make progress on their promised formularies.

Dr. Robert Goldberg to Speak at IRSG

Healthesystems’ Chief Medical Officer will present "Can Workers’ Comp Catch Up to the Rest of Healthcare?" at the 2018 IRSG Annual Conference.

FDA Approves New Opioid Prodrug, Apadaz

Apadaz oral tablets were approved for the short-term management of acute pain, at no more than 14 days of use.

Dr. Silvia Sacalis to Speak at National Rx Drug Abuse & Heroin Summit

Healthesystems' VP of Clinical Services will co-present Workers' Comp Opioid Use Trends and Effective Population Health Management.

Ohio BWC Reports Falling Levels of Opioid Dependence

The number of opioid-dependent injured workers in the Ohio workers' comp system fell 19% in 2017.

Air Ambulances: State v Federal Cost Control

Many states have attempted to implement fee schedules for air ambulances, but courts citing federal regulations have stricken them down.

State and City Lawsuits Continue to Mount Against Opioid Manufacturers

Forty-one states and over 200 cities and counties claim drug makers deceived patients and doctors regarding opioid safety and addiction risks.

Drug Recalls Impacting Comp

Senna Laxative bottles were found to contain NSAIDs, while 55 lots of compounded drugs face questionable sterility.

Medication Multiplication

A visual depiction of how opioid side effects can cascade across the body.

Increased Abuse Among Anti-Diarrhea Drugs

When taken in excessive doses, the anti-diarrhea drug loperamide can mimic opioid euphoria, and toxicity events and deaths are on the rise.

State Legislatures Increase Action Against Opioid Epidemic

The passage of opioid action plans in Arizona, Tennessee, and Pennsylvania are the most recent additions to growing statewide efforts to curb the epidemic.

The Rise of the Gig Economy

In 2003, gig workers made up less than 5% of the workforce. Today, estimates vary between 8% and 40%, raising questions for comp.

FDA Continues to Shift Opioid Strategy

2018 may hold more opioid policy revisions and the approval of new, non-opioid pain medications.

Artificial Intelligence and Workers’ Comp

Machine learning aims to automate parts of claims management.

No End in Sight for the Opioid Epidemic?

Despite decreases in prescribing rates, the opioid epidemic claims more lives than ever before, partially due to synthetic formulations.

State and Federal Governments Clash Over Marijuana

The Department of Justice’s recent announcement may come to a head with the will of state governments and popular opinion.

March of the Millennials

By 2020, millennials will make up half the workforce, so how will they impact workers’ comp?

FDA Approves Once-Monthly Buprenorphine Injection

Sublocade has been approved as the first once-monthly injectable buprenorphine product for opioid use disorder.

Dr. Silvia Sacalis Discusses Specialty Drug Trends with WorkCompWire

Healthesystems’ VP of Clinical Services covers specialty drug trends in workers’ comp, weighing costs alongside potential clinical benefits to injured workers.

New Study Ties Medical Marijuana to Reduced Opioid Use

A study from the University of New Mexico is the newest piece of research to link medical marijuana programs to decreased opioid use.

2018: The Year of Telemedicine?

While certain states move forward with telemedicine legislation, the market continues to grow, signaling a potential boom.

New RxInformer Clinical Journal Now Available

The Winter 2017 edition of Healthesystems’ clinical journal covering trending and influential topics in workers’ compensation is now available online.

Rexista Denied FDA Approval Over Abuse-Deterrent Properties

The FDA found that the abuse-deterrent properties of Rexista (oxycodone hydrochloride) extended-release tablets were not scientifically valid enough for approval.

Dr. Robert Goldberg Speaks to WC Magazine on Formularies

Healthesystems’ Chief Medical Officer was recently interviewed by WC Magazine on the growing popularity of workers’ comp formularies and the upcoming California formulary.

NCCI Analyzes Virginia’s Impending Fee Schedule Implementation

House Bill 378, which will implement the first workers’ compensation fee schedule in Virginia, takes effect January 1, 2018.

WCRI Reports on New York Opioid Use

When compared to a 26-state median, New York dispensed opioids to fewer claims, but the average opioid pill count per opioid claim was significantly higher.

Healthesystems at NWCDC 2017 in Las Vegas

Healthesystems will exhibit in booth #3707 from December 6-7. Our Clinical Pharmacist, Dr. Britten Featherston, will also co-present an educational session.

FDA Approves Zilretta for Osteoarthritis Knee Pain

Zilretta (triamcinolone acetonide extended-release injectable suspension) has been approved to manage osteoarthritis knee pain for 12-week intervals.

Healthesystems Pharmacists Named Finalists for Comp Laude Awards

Jeanette Connelly, PharmD, and Cheryl Hayes, PharmD, MBA are up for a prestigious award in workers’ comp for their commitment to ensuring the safety and appropriateness of pharmacotherapy for injured workers.

Acupuncture in Workers’ Comp

More clinical organizations support acupuncture as an alternative therapy to reduce opioid use, as do systematic reviews.

Arkansas Formulary Updates

The formulary implementation date has been changed to January 1, 2018, and the latest draft includes new opioid regulations.

Dr. Sacalis to Speak at WCI Emerging Trends Seminar Series

Healthesystems’ VP of Clinical Services will co-present Advancing Your Return to Work Program at the Workers’ Compensation Institute’s (WCI) Emerging Trends Seminar Series.

FDA Designates MDMA a Breakthrough Therapy in PTSD

The FDA gave the go-ahead for methylenedioxymethamphetamine (MDMA), the primary ingredient for the party drug ecstasy, to move forward with Phase 3 trials in patients with post-traumatic stress disorder (PTSD).

Dr. Robert Goldberg Speaks to Risk & Insurance on Physician Dispensing

Healthesystems’ Chief Medical Officer spoke with Risk & Insurance magazine on how the workers’ comp industry has managed this trend.

Ohio BWC Reports Reduced Opioid Usage

In 2016, 44% fewer injured workers received opioids when compared to 2011.

California DWC Moves to Update MTUS

As the California formulary will be based on ACOEM treatment guidelines, the MTUS may soon move away from ODG.

NCCI State Advisory Forums Highlight State-Specific Issues

Thirty-six member states plan to release reports detailing various trends in workers’ compensation.

FDA Approves Two New Hepatitis C Drugs

Mavyret and Vosevi are both indicated to treat HCV genotypes 1-6 without cirrhosis or with mild cirrhosis.

Tate Rice: Use of Virtual Reality and Video Games in Physical Therapy

Healthesystems’ Director of Physical Medicine discusses virtual reality with IAIABC.

Shifting Physician Dispensing Patterns

WCRI reports that while physicians dispensing has decreased after legislative reform, spending remains high due to new prescribing patterns.

Missouri to Enact PDMP

Executive Order 17-18 will make Missouri the final state in the U.S. to enact a prescription drug monitoring program.

DEA Proposes Descheduling Naldemedine

The DEA has found that the opioid-induced constipation drug appears to have very low abuse potential.

Non-Opioid Pain Medication Gets Fast Track Designation

Tanezumab, a biologic currently in Phase 3 development for chronic low-back pain, may benefit from increased FDA communications.

Healthesystems at WCI Orlando

Healthesystems will exhibit in booth #914 from August 7-9, and our VP of Clinical Services, Dr. Silvia Sacalis, will join a panel presentation on opioid best practices.

CDC Vital Signs – Opioid Prescribing Still High, Differs by County

While opioid prescribing rates have declined over the last several years, MME per person has tripled since 1999.

Texas Aims to Close Compounding Loophole

The Division of Workers’ Compensation released an informal working draft of a rule change that would exclude compounds from the state formulary.

Polypharmacy: How Many Drugs is Too Many?

The cost and safety concerns of multiple simultaneous drug regimens.

FDA Requests Removal of Opana ER, Reexamines Abuse-Deterrent Opioids

After requesting a manufacturer remove the opioid Opana ER from the market, the FDA announced a public meeting to discuss the real-world impact of abuse-deterrent opioids.

How Off-Label Prescribing Drives a Claim Off Course

How can common forms of off-label prescribing impact claim costs and outcomes?

New York Workers’ Comp Formulary Update

The New York Workers’ Compensation Board has clarified a deadline for formulary selection and rule development, along with certain formulary requirements.

Illicit Opioid Use Linked to Hepatitis C

The CDC found that Hepatitis C infections tripled in the last five years due to drug use related to the opioid epidemic.

Dr. Silvia Sacalis Discusses the Need for Early Opioid Interventions

Healthesystems’ VP of Clinical Services spoke with Business Insurance on the importance of preventing opioid misuse to avoid long-term complications.

FDA Approves New Opioid: RoxyBond

The FDA approved RoxyBond^® (oxycodone hydrochloride) tablets for the treatment of pain for which alternative treatments are inadequate.

Not-So Science Fiction: Innovative Technologies in Workers’ Comp

Learn how brain-computer interface, exoskeletons, 3D printing and virtual reality can impact workers’ comp.

Utah Bill May Allow Insurers to Enforce Opioid Prescribing Policies

House Bill 90 went into effect May 9th, allowing group health and workers’ comp insurers to enforce evidence-based opioid prescribing policies.

Are Opioid-Related Deaths Underreported?

A CDC report ties several unexplained deaths in Minnesota to opioid use, indicating that more deaths nationwide could be opioid-related than previously thought.

WorkCompWire Interviews Daryl Corr

Healthesystems CEO, Daryl Corr, was recently featured in a “RIMS Review” by WorkCompWire, in which he discusses formularies, a more adherent healthcare model, and protecting data.

Symproic^® Approved for Opioid-Induced Constipation

The FDA approved Symproic® (naldemedine) oral tablets for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain.

Future Opioids and the Injured Worker: Why “Safer” is a Relative Term

Drug makers are developing new opioids with potential safety improvements over old formulations, but do they fall short for injured workers?

New York to Enact Workers’ Comp Formulary

The passage of Assembly Bill A3009C calls for a workers’ comp formulary by 2018.

How Initial Opioid Use Impacts Long-Term Opioid Use

Data from 1.3 million patients reveals how early prescribing decisions can influence long-term opioid use.

Successful Speaking Events in Atlanta and Denver

Healthesystems clinical leaders recently presented at the National Rx Drug Abuse & Heroin Summit in Atlanta, Georgia, and at the American Occupational Health Conference in Denver, Colorado.

Olinvo (oliceridine) Completes Phase III Clinical Trials

An opioid developed to reduce adverse effects yielded lower rates of certain opioid-related side effects, but only in low drug doses.

Dr. Robert Goldberg Comments on Virtual Reality in Workers’ Comp

VR application in workers’ comp has great promise, but clinical guidelines are still years away.

Formularies Continue to Gain Steam

Pennsylvania, Kentucky, and Nebraska join the many states considering workers’ comp formularies.

ACP Releases Guideline for Chronic Low Back Pain

New guideline emphasizes non-pharmacologic treatments and alternative therapies.

Focus On: Opioid Overdose and Dependence Therapies

Claims considerations for the opioid-overdose drug naloxone, and the opioid-dependency drug buprenorphine.

FDA Approves Two New Opioids, New Dose for Narcan Nasal Spray

The FDA approved Arymo ER, Vantrela ER and a new 2mg dose of the opioid overdose reversal agent, Narcan.

Naloxone: The Path to Increased Patient Access

How has innovation and legislation impacted naloxone use?

Brain-Computer Interface: New Research

Providing mobility for paralyzed patients?

More State Limits on Opioid Prescriptions?

New Jersey, Utah, Indiana, Oregon and Maryland consider opioid prescription limits.

Compound Drug Trends in Florida

Compound spending has decreased as pharmacies dispense fewer compounds, but prescriber-dispensing continues to increase.

Safer Opioids?

Manufacturers are working to develop opioids with fewer adverse effects.

Expect More State Formulary Action in 2017

Momentum behind state formularies will continue, especially as current data help inform what is working and what can be improved.

Incoming Exoskeleton Boom?

They work, they are expensive, and everyone wants to build them.

Mandatory PDMP Use

Legislation hints at a new trend, one that takes the effectiveness of PDMPs to a new level.

Telemedicine: Slowly But Surely

It’s been championed as a new tool for workers’ comp. But are there enough data on telemedicine to expect large-scale implementation?

Cantrell Drug Company Issues Voluntary Recall Due to Lack of Sterility Assurance

Common workers’ comp drugs impacted by the recall include fentanyl, hydromorphone, morphine sulfate, and lidocaine.

Using Multidimensional Data to Estimate Potential Opioid Misuse

Analyzing multidimensional data across a broad patient population can reveal hidden risk factors for opioid misuse.

Department of Health and Human Services Expands Buprenorphine Access

Nurse practitioners and physician assistants will soon be able to prescribe the opioid dependence drug buprenorphine for up to 30 patients.

California DWC Formulary Webinar

Dr. Robert Goldberg, Healthesystems’ chief medical officer, will host an educational webinar for WOEMA on Wednesday, December 21 at 12:00 PM PT.

What Should Claims Professionals Know About Therapeutic Duplication?

The prescribing of multiple medications for the same indication can lead to serious safety and cost concerns.

New Evzio Strength Approved

The FDA approved a new 2 mg strength of Evzio (naloxone hydrochloride) auto-injector for the emergency treatment of opioid overdose.

Compound Medications: A Formula for Disaster

Often prescribed to treat pain associated with workplace injury, compounds are less regulated than FDA-approved drugs, resulting in significant patient safety and cost concerns.

WCRI Measures Opioid Use Between States

States with closed drug formularies and strong PDMP usage saw decreases in opioids per claim.

New York Expresses Interest in Workers' Comp Drug Formulary

The New York Workers' Compensation Board (WCB) announced their intent to establish a workers' comp prescription drug formulary.

Connect with Healthesystems at NWCDC 2016 in New Orleans

As proud gold sponsors of NWCDC 2016, Healthesystems invites you to visit us at booth 1419, and to attend one of our speaking sessions.

FDA Approves Biosimilar Amjevita

The FDA approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases.

Don't Overlook the Impact of Age and Comorbidity

With the number of claims including a comorbidity almost tripling in the last decade, how do comorbid conditions impact pharmacy management in the injured worker?

Ohio BWC Limits Opioid Reimbursements

Effective October 1st, the Ohio Bureau of Workers\' Compensation will only reimburse opioid prescriptions that adhere to best medical practices.

DEA Reduces Opioid Manufacturing Quotas for 2017

Schedule I and II drugs will see manufacturing quotas drop by 25% or more for 2017.

Dr. Goldberg Comments on California PDMP Law

Dr. Robert Goldberg, Chief Medical Officer, spoke with WorkCompCentral on California's new law requiring prescribers to consult the state prescription drug monitoring program before prescribing Schedule II-IV drugs.

FDA Approves New Opioid: Troxyca ER

The FDA approved Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules for severe pain. The new product has been labeled as abuse-deterrent.

Medically Speaking: Marijuana and Pain Management

With state and federal legislation expanding the use and research of medical marijuana, what does the data say about marijuana and pain?

NCCI Reports on Prescription Drug Costs in Workers' Comp

A new update by NCCI shows prescription drug spending comprises 17% of total workers' comp medical costs, despite decreased utilization.

California DWC Releases Draft Formulary Regulations

The formulary seeks to improve quality of care, and to reduce frictional costs and the cost of prescription drugs.

Dr. Sacalis to Speak at CWC & Risk Conference

Dr. Silvia Sacalis, VP of Clinical Services, will co-present Integration Is the Key to Managing Claim Complexities at the CWC & Risk Conference.

FDA Approves Relistor Tablets for Opioid-Induced Constipation

The FDA approved Relistor tablets (methylnaltrexone bromide) for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain.

Gender Considerations in Workers' Compensation

Do women face increased risks with prescription pain medications?

Impacts of Physician Dispensing Reforms

New cost drivers have emerged to offset savings from state-wide physician dispensing reforms, according to WCRI.

New State Opioid Limits

New York passed A10727, limiting initial opioid prescriptions for acute pain to a seven-day supply, joining other states that have enacted similar laws.

Topical Convenience Packs

Low-cost drug products face severe and unnecessary increases in price when they are packaged together in convenience packs, often with no medical benefit.